Shenzhen Regis Biotechnology

Regis Biotechnology is a clinical-stage biotechnology company headquartered in Shenzhen, China, focusing on the development of mRNA-based therapeutics and vaccines. Founded in 2019, the company has developed a proprietary R-mRNA platform that integrates mRNA sequence design, modified nucleotide technology, and lipid nanoparticle (LNP) delivery systems. Its lead program, RH109, is a lyophilized mRNA vaccine for COVID-19 that has demonstrated high stability and efficacy in clinical trials. Beyond infectious diseases, Regis is expanding its pipeline into personalized cancer vaccines and protein replacement therapies for metabolic disorders. The company maintains multiple R&D and manufacturing facilities across China to support its end-to-end mRNA drug development capabilities.